Ana Rima Setijadi
Universitas Sebelas Maret

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

Concordance Rate Between Examination of EGFR Mutation Blood Plasma Sample (ctDNA) With Citological/Histopathological Sample in Adenocarcinoma Lung Cancer Dian Utami Wulaningrum; Ana Rima Setijadi; Suradi Suradi
Respiratory Science Vol. 1 No. 1 (2020): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v1i1.9

Abstract

Background: Most adenocarcinoma lung cancer which is found at an advanced stage with cytology / histopathological samples is hardly available. Examination of EGFR mutations in ctDNA blood plasma sampling is simpler and easier, which also can be used as predictive and prognostic markers in non-small cell carcinoma lung cancer patients. The purpose of this study is to determine and analyse the degree of compatibility between examination of EGFR mutations by blood plasma (ctDNA) samples with the examination of cytology / histopathological EGFR mutations in adenocarcinoma lung cancer. Methods: Diagnostic test research, by taking medical records of patients with adenocarcinoma lung cancer from January to September 2019 at Dr. Moewardi Surakarta, who was examined by EGFR mutations in cytology / histopathology and ctDNA samples. Result: The Subjects of this study were 73 patients with adenocarcinoma lung cancer. The level of compatibility of ctDNA with EGFR mutations in cytology / histopathology samples was categorized as moderate and statistically significant (Kappa = 0.459; p = 0.000). Conclusion: The level of concordance between the examination of EGFR mutations with blood plasma samples (ctDNA) with the examination of EGFR mutations in cytology / histopathology samples was moderate and statistically significant.
The Delay in The Diagnosis of Lung Cancer Due to Misdiagnosis as Pulmonary Tuberculosis Jatu Aviani; Satria Maulana EH; Ita Haryatie; Farih Raharjo; Yusup Subagio Sutanto; Ana Rima Setijadi
Jurnal Respirologi Indonesia Vol 37, No 4 (2017)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (422.907 KB) | DOI: 10.36497/jri.v37i4.83

Abstract

Background: Lung cancer and pulmonary tuberculosis (TB) are global health problem. Similarity of symptoms of both made misdiagnose of lung cancer as TB and treated with Anti Tuberculosis Treatment (ATT). Evaluation of ATT often inaccurate, causing late diagnosis of lung cancer. This study aimed is to determine the lung cancer percentage with delayed diagnosis due giving of ATT for >1 month. Methods: A prospective descriptive study was performed from January 2014-February 2016 in Dr. Moewardi Hospital, Surakarta taken from the patient's medical record. Results: As much 293 patients with lung cancer consisted of 188 males (64.4%) and 105 females (35.8%) with the average age was 57 years old. The types of the lung cancer were non-small cell lung carcinoma (NSCLC) consisted of adenocarcinoma 195 subjects (66.6%), squamous cell carcinoma 65 subjects (22.2%), large cell carcinoma 23 subjects (7.8%) and neuroendocrine carcinoma 4 subjects (1.4%). The stages of the NSCLC were stage I (0%), II (0%), IIIa (0%), IIIb (11.7%) and IV (88.3%). Among 293 lung cancer patients, 89 subjects (30.4%) were diagnosis as pulmonary TB. Two subjects (2.2%) of 89 subjects were truly pulmonary TB while the rest 87 subjects were not pulmonary TB and had ATT for average 12 weeks with the longest period was 16 weeks. The ATT duration >1 month was 76.4%. Conclusions: Percentage of lung cancer patients with ATT before being referred to dr. Moewardi hospital were 30.4% of 293 lung cancer patients while 68 subjects (76.4%) of whom had received ATT >1 month. (J Respir Indo. 2017; 37(4): 288-92)
The Effect of Curcumin On Plasma Histamine Level, PEF Variation and Length of Stay of Patients With Acute Exacerbation Asthma Lydia Arista Sutedjo; Suradi Suradi; Ana Rima Setijadi
Jurnal Respirologi Indonesia Vol 38, No 2 (2018)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v38i2.164

Abstract

Introduction: Inflammation in asthma occured in airway especially in submucous layer, and involve eosinophil, neutrophil, lymphocytes T, epitheliat cel, basophil, mast cell, and lymphocytes B. Inflammatory cells produce inflammatory mediators (histamine, leucotrienes, and prostanoid), cytokines, and chemokines that can cause bronchocontriction. This study was conducted to determine and prove the effect of curcumin as adjunctive therapy in acute exacerbation asthma. Curcumin is expected to increase the quality therapy of acute exacerbation asthma. The effect of curcumin is known wiith evaluate plasma histamine level, PEF variation, and length of stay of patient with acute exacerbation asthma. Methods: This study is a quasi experimental study with pretest and posttest design. Sampel of study is 30 patients hospitalizes acute exacerbation asthma in Moewardi hospital and Sohadi Prijonegoro Sragen hospital in August 2016 until september 2016. The subject was taken with concecutive random sampling. Independent variable is curcumin 4x550 mg and dependent variables are plasma histamin level, PEF variation, and length of stay. Result: There is no significant difference (P=0.462) of decreasing plasma histamine level between treatment group 3,988±2,739 ng/ml and control group 3,376±1,606 ng/ml. There is no significant difference (P=0.501) of PEF variation between treatment group 28,126±7,886% and control group 30,400±10,217%. There is no significant difference (P=0.936) of length of stay between treatment group perlakuan 6,333±2,193 days and control group 6,400±2,292 days. Conclusion: Giving curcumin in acute exacerbation asthma while hospitalized didn’t reduce inflammatory marker plasma histamin, PEF variation, and length of stay. (J Respir Indo 2018; 38(2): 100-8)
The Role of Incentive Spirometry On Exercise Capacity, Breathing Symptoms, Depression Rate, and Quality of Life in NSCLC Patients with Chemotherapy Dian Apriliana; Suradi Suradi; Ana Rima Setijadi
Respiratory Science Vol. 2 No. 1 (2021): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v2i1.33

Abstract

Backgrounds: Pulmonary rehabilitation is a non-pharmacological therapy that improves breathing capacity in lung cancer patients. This study aimed to determine the effects of incentive spirometry (IS) on exercise capacity, breathing symptoms, depression rates, and quality of life in lung cancer patients with chemotherapy. Method: This quasi-experimental study was done through purposive sampling of 32 lung cancer patients who underwent chemotherapy for at least three cycles at Dr. Moewardi General Regional Hospital, Surakarta, from December 2019 to February 2020.Data on 6 minutes walking test (6-MWT) to evaluate exercise capacity, breathing symptoms (BORG scale), level of depression (HRSD questionnaire), and quality of life (SGRQ questionnaire) . Results: Experimental group showed higher value of 6-MWT (72.75±152.50 meters vs. 31.81 ± 27.67, P=0.010), a decrease in the BORG scale (-1.78±1.72 vs. -0.38±1.67, P=0.013), Hamilton's score improvement (-2.25±5.12 vs. -4.25±5.34, P=0.075), and improvement in the SGRQ value (-10.77±9.82 vs. -0.08±11.16, P=0.752) compared to those of control group.